Evidence map›Paper›PMID 41089232›Full record

ArticleIJTLD open2025

Acceptability of 100-mg moxifloxacin in children with rifampicin-resistant TB in three high-burden countries.

N Suryavanshi, H R Draper, G Dhumal, S Bagchi, N T Castillo-Carandang, A Marthinus, A M A Cheong, A Kinikar, M Paradkar, A Gupta and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in IJTLD open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

N SuryavanshiByramjee Jeejeebhoy Government Medical College, Johns Hopkins Clinical Research Site, Pune, India.
H R DraperDesmond Tutu TB Centre, Department of Paediatrics and Child Health, Stellenbosch University, Stellenbosch, South Africa.
G DhumalByramjee Jeejeebhoy Government Medical College, Johns Hopkins Clinical Research Site, Pune, India.
S BagchiByramjee Jeejeebhoy Government Medical College, Johns Hopkins Clinical Research Site, Pune, India.
N T Castillo-CarandangDepartment of Clinical Epidemiology, College of Medicine, University of the Philippines, Manila, Philippines.
A MarthinusDesmond Tutu TB Centre, Department of Paediatrics and Child Health, Stellenbosch University, Stellenbosch, South Africa.
A M A CheongDe La Salle Health Sciences Institute, Dasmariñas City, Philippines.
A KinikarDepartment of Paediatrics, Byramjee Jeejeebhoy Government Medical College, Pune, India.
M ParadkarByramjee Jeejeebhoy Government Medical College, Johns Hopkins Clinical Research Site, Pune, India.
A GuptaDepartment of Infectious Disease, School of Medicine, Johns Hopkins University, Baltimaore, MD, USA.
J D R OcampoDepartment of Pediatrics, School of Medicine and Public Health, University of Wisconsin, Madison, WI, USA.
M V G FriasDepartment of Clinical Epidemiology, College of Medicine, University of the Philippines, Manila, Philippines.
D J O CasalmeDepartment of Clinical Epidemiology, College of Medicine, University of the Philippines, Manila, Philippines.
A HesselingDesmond Tutu TB Centre, Department of Paediatrics and Child Health, Stellenbosch University, Stellenbosch, South Africa.
A J Garcia-PratsDesmond Tutu TB Centre, Department of Paediatrics and Child Health, Stellenbosch University, Stellenbosch, South Africa.
M PalmerDesmond Tutu TB Centre, Department of Paediatrics and Child Health, Stellenbosch University, Stellenbosch, South Africa.
G HoddinottDesmond Tutu TB Centre, Department of Paediatrics and Child Health, Stellenbosch University, Stellenbosch, South Africa.
L ViljoenDesmond Tutu TB Centre, Department of Paediatrics and Child Health, Stellenbosch University, Stellenbosch, South Africa.
CATALYST Trial Team

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRoutinely, a 400-mg tablet of moxifloxacin is used in children with rifampicin-resistant TB (RR-TB), but it has very poor acceptability. We describe the acceptability of a 100-mg dispersible moxifloxacin among children and their caregivers in South Africa, India, and the Philippines.

methodsThis study is nested in a pharmacokinetics, safety, and acceptability trial of new formulations of clofazimine and moxifloxacin in children with RR-TB. Quantitative and qualitative data were collected at four time points over 24 weeks and were analysed descriptively and thematically.

findingsMedian age of participants (n = 36) was 4.9 years. Children and caregivers from all three countries preferred the dispersible 100-mg moxifloxacin to the routine 400-mg tablet due to the relative ease of administration. The 100-mg formulation was unpalatably bitter. Children who were able to swallow the 100-mg formulation preferred to do so. The smaller size of the 100-mg tablets enhanced their ease of preparation and acceptability, although some older participants experienced the increase in the number of tablets (compared with single 400-mg tablet) as a burden.

conclusionThe 100-mg moxifloxacin dispersible formulation is preferred over 400-mg. Overall, moxifloxacin palatability remains sub-optimal, and there is a need to further improve the acceptability of RR-TB treatments for children.

Indexed as

dispersible drugDR-TBdrug-resistantpalatabilitytuberculosis

Identifiers

PMID41089232
PMCPMC12517267

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.